Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089973 · ClinicalTrials.gov registry record · Phase 2
Study Of Ispinesib In Subjects With Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00089973 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants.
The verdict
NCT00089973, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to Ispinesib? 2. What are the side effects of Ispinesib? 3. How much Ispinesib is in the blood at specific times after it is taken?
Interventions
- DRUG Ispinesib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-06-30 |
| Est. Completion | 2006-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089973
The ClinicalTrials.gov registry entry for NCT00089973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ispinesib is the first listed.
NCT00089973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089973 about?
NCT00089973 is a clinical study titled "Study Of Ispinesib In Subjects With Breast Cancer". The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to fin...
What is the current status of trial NCT00089973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-06-30. Estimated completion is 2006-08-25.
What interventions are being tested in trial NCT00089973?
The interventions under investigation include: Ispinesib (DRUG).
Who is sponsoring clinical trial NCT00089973?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.